Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Alligator Bioscience

0.17 SEK

+0.95 %

Less than 1K followers

ATORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.95 %
-14.74 %
-49.54 %
-49.54 %
-87.03 %
-91.09 %
-98.37 %
-99.80 %
-99.96 %

Alligator Bioscience is a research-based biotechnology company. The company uses a patented technology to develop biological drug candidates in inflammation and cancer, and is active in the earlier part of the drug development chain. Alligator Bioscience has a global technology platform and is active in the protein pharmaceutical segment. The company was founded in 2001 and is headquartered in Lund.

Read more
Market cap
106.78M SEK
Turnover
48.04K SEK
Revenue
514K
EBIT %
-20,588.72 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/5
2026

Interim report Q1'26

6/5
2026

General meeting '26

27/8
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release3/31/2026, 1:00 PM

Ändring av antalet aktier och röster i Alligator Bioscience AB

Alligator Bioscience
Regulatory press release3/31/2026, 1:00 PM

Change in number of shares and votes in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release3/30/2026, 6:45 AM

Notice of annual general meeting in Alligator Bioscience AB

Alligator Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/30/2026, 6:45 AM

Kallelse till årsstämma i Alligator Bioscience AB

Alligator Bioscience
Regulatory press release3/27/2026, 10:30 AM

Valberedningens förslag avseende styrelse inför årsstämman i Alligator Bioscience AB (publ)

Alligator Bioscience
Regulatory press release3/27/2026, 10:30 AM

The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

Alligator Bioscience
Regulatory press release3/26/2026, 2:00 PM

Alligator Bioscience publicerar årsredovisning för 2025

Alligator Bioscience
Regulatory press release3/26/2026, 2:00 PM

Alligator Bioscience publishes Annual Report for 2025

Alligator Bioscience
Regulatory press release3/20/2026, 2:30 PM

Alligator Bioscience AB meddelar utfall för nyttjandet av teckningsoptioner serie TO 14

Alligator Bioscience
Regulatory press release3/20/2026, 2:30 PM

Alligator Bioscience AB announces outcome of exercise of warrants series TO 14

Alligator Bioscience
Regulatory press release3/19/2026, 8:52 AM

Finansinspektionen: Flaggningsmeddelande i Alligator Bioscience AB

Alligator Bioscience
Press release3/18/2026, 7:50 AM

Nya data från prövarinitierad studie som utvärderar Alligator Biosciences mitazalimab kommer att presenteras vid AACR Annual Meeting 2026

Alligator Bioscience
Press release3/18/2026, 7:50 AM

New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026

Alligator Bioscience
Regulatory press release3/16/2026, 11:45 AM

Ledningen avser att teckna pro rata i Alligator Biosciences teckningsoptionsprogram TO 14

Alligator Bioscience
Regulatory press release3/16/2026, 11:45 AM

Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14

Alligator Bioscience
Press release3/10/2026, 12:30 PM

Alligator Bioscience strengthens intellectual property protection for bispecific antibody platform

Alligator Bioscience
Press release3/10/2026, 12:30 PM

Alligator Bioscience stärker immaterialrättsligt skydd för bispecifik antikroppsplattform

Alligator Bioscience
Press release3/2/2026, 7:45 AM

Alligator Bioscience kommenterar doseringen av första patienten i Henlius fas 2/3-studie med HLX22 vid bröstcancer

Alligator Bioscience
Press release3/2/2026, 7:45 AM

Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22

Alligator Bioscience
Regulatory press release2/27/2026, 5:30 PM

Teckningskurs fastställd för nyttjandet av teckningsoptioner serie TO 14 i Alligator Bioscience AB

Alligator Bioscience
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.